Ritter pharmaceuticals and qualigen announce merger agreement

Ritter pharmaceuticals, inc. and qualigen, inc. announce merger agreement.ritter pharmaceuticals inc - will merge with and into qualigen in an all-stock transaction with qualigen.ritter pharmaceuticals inc - upon completion of merger, company will change its name to qualigen, inc., or a similar name selected by qualigen.ritter pharmaceuticals - merged co will focus on development of qualigen's nanotechnology therapies for treatment of cancer and infectious diseases.ritter pharmaceuticals inc - pre-merger ritter pharmaceuticals stockholders will own approximately 7.5% of post-merger combined company.ritter pharmaceuticals inc - merged company will continue to operate its profitable diagnostic business.ritter pharmaceuticals - in conjunction with merger transaction, qualigen has arranged securing of additional capital from an institutional investor.ritter pharmaceuticals inc - under a separate cvr agreement, a cvr holder representative will continue to seek opportunities to monetize rp-g28 asset.ritter pharmaceuticals - qualigen arranged securing of additional capital from an institutional investor to support funding of its operations, expansion.ritter pharmaceuticals - michael poirier will be appointed to serve as combined co's chairman, president and ceo.ritter pharmaceuticals - board for post-merger combined co will be comprised of 7 directors, including 1 member from co's board.
QLGN Ratings Summary
QLGN Quant Ranking